Global Systemic Lupus Erythematosus Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Systemic Lupus Erythematosus Overview
  3. Therapeutics Development
  4. Pipeline Products for Systemic Lupus Erythematosus - Overview
  5. Pipeline Products for Systemic Lupus Erythematosus - Comparative Analysis
  6. Systemic Lupus Erythematosus - Therapeutics under Development by Companies
  7. Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes
  8. Systemic Lupus Erythematosus Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Systemic Lupus Erythematosus - Products under Development by Companies
  13. Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes
  14. Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
  • 4SC AG
  • AbbVie Inc.
  • Ablynx NV
  • ACEA Biosciences, Inc.
  • Actelion Ltd
  • Astellas Pharma Inc.
  • Baxalta Incorporated
  • Biogen, Inc.
  • Biotest AG
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genosco
  • Immupharma Plc
  • Invion Limited
  • Johnson & Johnson
  • K-Stemcell Co., Ltd.
  • Kadmon Corporation, LLC
  • Karyopharm Therapeutics, Inc.
  • Kolltan Pharmaceuticals, Inc.
  • Lead Discovery Center GmbH
  • LSK BioPartners, Inc.
  • MacroGenics, Inc.
  • MedAnnex Ltd
  • Neovacs SA
  • Principia Biopharma Inc.
  • RedHill Biopharma Ltd.
  • Redx Pharma Plc
  • Resolve Therapeutics, LLC
  • Sanofi
  • XTL Biopharmaceuticals Ltd.

For more information visit http://www.researchandmarkets.com/research/lzwggb/systemic_lupus

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs, Musculoskeletal Disorders Drugs